Adjunctive therapy with curcumin for peptic ulcer: A randomized controlled trial

Adjunctive therapy with curcumin for peptic ulcer: A randomized controlled trial - Curcumin supplementation for peptic ulcer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022106

Enrollment

Registered

2016-06-01

Start date

2016-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic ulcer disease

Interventions

Treatment group: Curcumin (500 mg/day) + piperine (5 mg/day) + standard anti-helicobacter triple therapy Treatment duration: 14 days Control group: Placebo (microcrystalline cellulose) + 5 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: diagnosis of clean-based gastric or duodenal ulcers in gastroscopy and presence of H. pylori infection based on the rapid urease test on the biopsy specimens of antral mucosa

Exclusion criteria

Exclusion criteria: History of receiving anti-helicobacter treatment, concomitant treatment with corticosteroids, chronic diseases, malignanices including gastric malignancy, and lack of adherence to the study protocol defined as non-compliance with the administered anti-helicobacter triple therapy, or changing the triple therapy regimen

Design outcomes

Primary

Measure	Time frame
Changes in the frequency and severity of peptic ulcer symptoms following curcumin supplementation for 14 days	—

Secondary

Measure	Time frame
Effect of curcumin supplementation (for 14 days) on the eradication of Helicobacter pylori	—

Countries

Asia(except Japan)

Contacts

Public ContactYunes Panahi

Baqiyatallah university of Medical Sciences, Tehran, Iran Chemical Injuries Research Center

yunespanahi@yahoo.com+982188211524

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026